Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2016 Jan 14

PMID 26757906

Citations 19

Authors

Qiang Li

Aditya Bagrodia

Eugene K Cha

Jonathan A Coleman

Affiliations

Soon will be listed here.

Abstract

Urothelial carcinoma is a highly heterogeneous disease that can arise throughout the entire urothelial lining from the renal pelvis to the proximal urethra. Upper tract urothelial carcinoma (UTUC) is rare, and while it shares many similarities with urothelial carcinoma of bladder (UCB), there are also significant differences between UTUC and UCB regarding clinical management and outcomes. No major advances have been made recently in the development of new systemic therapies for urothelial carcinoma, partly due to the lack of understanding of underlying molecular pathogenetic mechanisms. In the past decade, the emergence of next-generation sequencing has greatly enabled genomic characterization of tumor samples. Researchers are currently exploring a personalized approach to augment traditional clinical decision-making based on genetic alterations. In the present review, we summarize current genomic advances in UTUC and discuss the potential implications of these developments for developing prognostic and predictive biomarkers.

Citing Articles

Biomarker Profiling of Upper Tract Urothelial Carcinoma Only and with Synchronous or Metachronous Bladder Cancer.

Meireles S, Dias C, Martins D, Marques A, Dias N, Pacheco-Figueiredo L Biomedicines. 2024; 12(9).

PMID: 39335667 PMC: 11429062. DOI: 10.3390/biomedicines12092154.

Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database.

Zheng F, Du Y, Yuan Y, Wang Z, Li S, Xiong S Heliyon. 2024; 10(18):e37544.

PMID: 39309793 PMC: 11415710. DOI: 10.1016/j.heliyon.2024.e37544.

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.

Matsubara N, Miura Y, Nishiyama H, Taoka R, Kojima T, Shimizu N Int J Clin Oncol. 2024; 29(10):1516-1527.

PMID: 39017806 PMC: 11420312. DOI: 10.1007/s10147-024-02583-3.

Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.

Srinivasalu V, Robbrecht D Cancers (Basel). 2024; 16(13).

PMID: 39001460 PMC: 11240521. DOI: 10.3390/cancers16132398.

Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.

Mazzaschi G, Giudice G, Coriano M, Campobasso D, Perrone F, Maffezzoli M Technol Cancer Res Treat. 2023; 22:15330338231159753.

PMID: 36855829 PMC: 9983117. DOI: 10.1177/15330338231159753.

References

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F . Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107(15):6982-7. PMC: 2872463. DOI: 10.1073/pnas.1002472107. View

Kurtoglu M, Davarpanah N, Qin R, Powles T, Rosenberg J, Apolo A . Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2015; 13(5):410-20. PMC: 4561017. DOI: 10.1016/j.clgc.2015.02.009. View

Xiong G, Liu J, Tang Q, Fan Y, Fang D, Yang K . Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics. 2015; 7(5):733-44. DOI: 10.2217/epi.15.34. View

Rey A, Lara P, Redondo E, Valdes E, Apolinario R . Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer. 1997; 79(11):2178-85. DOI: 10.1002/(sici)1097-0142(19970601)79:11<2178::aid-cncr16>3.0.co;2-t. View

Smith S, Baras A, Lee J, Theodorescu D . The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010; 70(5):1753-8. PMC: 2831138. DOI: 10.1158/0008-5472.CAN-09-3562. View

Mitchell S, Mayer E, Patel A . Expression of p53 in upper urinary tract urothelial carcinoma. Nat Rev Urol. 2011; 8(9):516-22. DOI: 10.1038/nrurol.2011.92. View

Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M . European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013; 63(6):1059-71. DOI: 10.1016/j.eururo.2013.03.032. View

van Oers J, Zwarthoff E, Rehman I, Azzouzi A, Cussenot O, Meuth M . FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2008; 55(3):650-7. DOI: 10.1016/j.eururo.2008.06.013. View

Rigola M, Fuster C, Casadevall C, Bernues M, Caballin M, Gelabert A . Comparative genomic hybridization analysis of transitional cell carcinomas of the renal pelvis. Cancer Genet Cytogenet. 2001; 127(1):59-63. DOI: 10.1016/s0165-4608(00)00426-x. View

10.

Wu S, Chen J, Dong P, Zhang S, He Y, Sun L . Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma. BMC Cancer. 2014; 14:836. PMC: 4242595. DOI: 10.1186/1471-2407-14-836. View

11.

Amira N, Rivet J, Soliman H, Cancel-Tassin G, Le Duc A, Janin A . Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol. 2003; 170(4 Pt 1):1151-4. DOI: 10.1097/01.ju.0000086551.22844.cd. View

12.

Izquierdo L, Truan D, Mengual L, Mallofre C, Alcaraz A . HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res. 2010; 30(6):2439-45. View

13.

Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M . Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res. 2010; 16(23):5814-23. DOI: 10.1158/1078-0432.CCR-10-0230. View

14.

Chang W, Lin S, Li F, Tsai C, Li L, Lien C . Significant association of caveolin-1 (CAV1) genotypes with upper urothelial tract cancer. Anticancer Res. 2013; 33(11):4907-12. View

15.

Hashimoto H, Sue Y, Saga Y, Tokumitsu M, Yachiku S . Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter. Int J Urol. 2001; 7(12):457-63. DOI: 10.1046/j.1442-2042.2000.00230.x. View

16.

Izquierdo L, Truan D, Petit A, Gutierrez R, Mallofre C, Alcaraz A . Adhesion molecules alpha, beta and gamma-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT-P/GSK-3beta/beta-catenin pathway. BJU Int. 2009; 104(1):100-6. DOI: 10.1111/j.1464-410X.2008.08292.x. View

17.

Jeong I, Kim S, Jeon H, Kim B, Moon K, Lee S . Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol. 2009; 40(5):668-77. DOI: 10.1016/j.humpath.2008.10.010. View

18.

Leibl S, Zigeuner R, Hutterer G, Chromecki T, Rehak P, Langner C . EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS. 2008; 116(1):27-32. DOI: 10.1111/j.1600-0463.2008.00859.x. View

19.

Wang Y, Li W, Wu W, Chai C, Liu H, Lai M . Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: crosstalk with ErbB2-PI3K-Akt pathway. J Urol. 2013; 192(1):242-51. DOI: 10.1016/j.juro.2013.12.001. View

20.

Phe V, Cussenot O, Roupret M . Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 2009; 104(7):896-901. DOI: 10.1111/j.1464-410X.2009.08696.x. View